Astria Therapeutics, Inc. (NASDAQ: ATXS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Astria Therapeutics, Inc. (NASDAQ: ATXS) had its price target raised by analysts at Oppenheimer Holdings Inc. from $26.00 to $28.00. They now have an "outperform" rating on the stock.
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update [Yahoo! Finance]
Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference